PAVmed (PAVM) Price & Analysis

Compare

645 Followers

PAVM Stock Chart & Stats

$0.29

-$0.02(-2.96%)

At close: Jan 08 4:00 PM EST

$0.29

-$0.02(-2.96%)

Day’s Range― - ―

52-Week Range$0.30 - $0.90

Previous CloseN/A

Volume127.06K

Average Volume (3M)377.79K

Market Cap

$8.58M

Enterprise Value$34.62M

Total Cash (Recent Filing)$3.10M

Total Debt (Recent Filing)$9.28M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Mar 31, 2026

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding29,671,925

10 Day Avg. Volume774,204

30 Day Avg. Volume377,786

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-2.43

Price to Sales (P/S)2.03

P/FCF Ratio-0.18

Enterprise Value/Market Cap4.03

Enterprise Value/Revenue509.14

Enterprise Value/Gross Profit-70.95

Enterprise Value/Ebitda-3.96

Forecast

1Y Price Target

$17.00

Price Target Upside5762.07% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Growth And CommercializationLucid's high growth and ramp up in commercialization will be a major catalyst for PAVmed’s stock, with imminent Medicare coverage expected by early 2026.

Strategic PartnershipsVeris Health is launching innovative digital health tools to improve personalized cancer care, with a strategic partnership with The Ohio State's James Cancer Hospital to implement a pilot program.

Valuation And Price PotentialCurrent valuation is considered attractive, with a BUY rating maintained and significant upside potential from the current share price.

Bears Say

Development ChallengesPAVmed’s devices still have long development and commercialization challenges ahead, despite the high market potential.

PAVmed News

Lucid Diagnostics’ esophageal precancer detection tools show efficacy in study

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced new data from the largest reported real-world experience of...

19d ago

LUCD

PAVM

PAVmed Approves Reverse Stock Split Amendment

PAVmed ( ($PAVM) ) has issued an update. On December 5, 2025, PAVmed Inc. held a special meeting...

23d ago

PAVM

Pavmed Inc. Reports Q3 2025 Earnings and Strategic Focus

Pavmed ( ($PAVM) ) has released its Q3 earnings. Here is a breakdown of the information Pavmed presented...

1M ago

PAVM

PAVmed’s Earnings Call: Triumphs and Trials

Pavmed (($PAVM)) has held its Q3 earnings call. Read on for the main highlights of the call. PAVmed’s...

1M ago

PAVM

PAVM Upcoming Earnings Report: What to Expect?

Pavmed (PAVM) is scheduled to report 3rd quarter earnings on 11/18/2025. Regarding Q3 estimates, Wall Street analysts expect...

1M ago

PAVM

PAVmed Announces Q3 2025 Financial Results and Updates

PAVmed ( ($PAVM) ) has shared an announcement. On November 13, 2025, PAVmed Inc. announced a business update...

2M ago

PAVM

PAVmed’s Lucid Diagnostics Completes Public Stock Offering

The latest update is out from PAVmed ( ($PAVM) ). On September 11, 2025, Lucid Diagnostics Inc., a...

4M ago

PAVM

PAVmed to license esophageal imaging technology from Duke Technology

PAVmed (PAVM) has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary,...

4M ago

PAVM

PAVmed Reports Q2 2025 Financial Results and Developments

The latest update is out from PAVmed ( ($PAVM) ). In its second quarter of 2025, PAVmed Inc....

5M ago

PAVM

PAVmed reports Q2 non-GAAP EPS (5c) vs. (84c) last year

Reports Q2 revenue $6K vs. $979K last year. PAVmed (PAVM) had cash and cash equivalents of $4.0M as...

5M ago

PAVM

Lucid Diagnostics Reports Q2 2025 Financial Results

Pavmed ( ($PAVM) ) has released its Q2 earnings. Here is a breakdown of the information Pavmed presented...

5M ago

PAVM

PAVmed Granted Nasdaq Extension for Compliance

An update from PAVmed ( ($PAVM) ) is now available. On July 29, 2025, PAVmed Inc. received a...

5M ago

PAVM

PAVmed Inc. Completes First in Human Trial of PortIO Intraosseous Infusion System

PAVmed Inc (($PAVMU)), Pavmed (($PAVM)) announced an update on their ongoing clinical study. The recent clinical study update...

6M ago

PAVM

PAVmed subsidiary Veris Health partners with Ohio State University cancer center

PAVmed’s (PAVM) majority-owned digital health subsidiary Veris Health has entered into a strategic partnership agreement with The Ohio...

7M ago

PAVM

PAVM FAQ

What was PAVmed Inc’s price range in the past 12 months?

PAVmed Inc lowest stock price was $0.30 and its highest was $0.90 in the past 12 months.

What is PAVmed Inc’s market cap?

PAVmed Inc’s market cap is $8.58M.

When is PAVmed Inc’s upcoming earnings report date?

PAVmed Inc’s upcoming earnings report date is Mar 31, 2026 which is in 93 days.

How were PAVmed Inc’s earnings last quarter?

PAVmed Inc released its earnings results on Nov 13, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.12.

Is PAVmed Inc overvalued?

According to Wall Street analysts PAVmed Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PAVmed Inc pay dividends?

PAVmed Inc does not currently pay dividends.

What is PAVmed Inc’s EPS estimate?

PAVmed Inc’s EPS estimate is -0.18.

How many shares outstanding does PAVmed Inc have?

PAVmed Inc has 29,671,925 shares outstanding.

What happened to PAVmed Inc’s price movement after its last earnings report?

PAVmed Inc reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -10.256%.

Which hedge fund is a major shareholder of PAVmed Inc?

Currently, no hedge funds are holding shares in PAVM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PAVmed Inc

PAVmed Inc. is a medical technology company focused on the development and commercialization of innovative medical devices and diagnostic tools. Operating primarily in the healthcare sector, PAVmed aims to improve patient outcomes through its core products, which include devices for gastroenterology, urology, and other specialty areas. The company is known for its commitment to addressing unmet medical needs with solutions that enhance clinical workflows and patient care.

PAVmed (PAVM) Earnings & Revenues

Historic Earnings Reports

PAVM Company Deck

PAVM Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted several significant achievements, including successful Medicare endorsement for EsoGuard, strong financial positioning for Lucid, and strategic partnerships for Veris. However, challenges remain in debt restructuring and stagnant EsoGuard revenue growth.View all PAVM earnings summaries

PAVM Stock 12 Month Forecast

Average Price Target

$17.00

▲(5762.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","-1":"-$1","3.75":"$3.75","8.5":"$8.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3.75,8.5,13.25,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,1.6307692307692307,2.9115384615384614,4.192307692307692,5.473076923076922,6.753846153846153,8.034615384615384,9.315384615384614,10.596153846153845,11.876923076923076,13.157692307692306,14.438461538461537,15.719230769230768,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,1.6307692307692307,2.9115384615384614,4.192307692307692,5.473076923076922,6.753846153846153,8.034615384615384,9.315384615384614,10.596153846153845,11.876923076923076,13.157692307692306,14.438461538461537,15.719230769230768,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,1.6307692307692307,2.9115384615384614,4.192307692307692,5.473076923076922,6.753846153846153,8.034615384615384,9.315384615384614,10.596153846153845,11.876923076923076,13.157692307692306,14.438461538461537,15.719230769230768,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.63,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.52,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.43,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >